NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding
Over 800 People With Urothelial Cancer Set To Benefit From Bavencio
Executive Summary
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.